Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research Mireille Langouo FontsaMarco Maria AielloCinzia Solinas Review Article 14 September 2022 Pages: 497 - 505
Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis Evangelos DigkasAnthony Jagri TabiimAntonis Valachis Systematic Review Open access 01 August 2022 Pages: 507 - 515
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma Ghassan K. Abou-AlfaKristen BibeauLuis Féliz Original Research Article Open access 17 September 2022 Pages: 517 - 527
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma Jennifer J. GileVanessa WookeyAmit Mahipal Original Research Article 02 September 2022 Pages: 529 - 538
Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm Sophie O’HaireKoen DegelingMaarten IJzerman Original Research Article Open access 05 September 2022 Pages: 539 - 548
Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists Andrew J KlinkAbhishek KavatiRuth Antoine Original Research Article Open access 11 September 2022 Pages: 549 - 561
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors Iris Y. ShengShilpa GuptaAlok A. Khorana Original Research Article 20 August 2022 Pages: 563 - 569
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies Matteo SantoniJavier Molina-CerrilloNicola Battelli Original Research Article 10 August 2022 Pages: 571 - 581
Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis Asuka SanoYusuke InoueHideaki Miyake Original Research Article 12 September 2022 Pages: 583 - 589
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis Margherita RiminiValentina BurgioAndrea Casadei-Gardini Short Communication 17 September 2022 Pages: 591 - 596
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors Makoto NishioTerufumi KatoToyoaki Hida Therapy in Practice Open access 10 September 2022 Pages: 597 - 604
Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta‑Analysis Daqi JiaLeilei LiPeng Wang Letter to the Editor 01 August 2022 Pages: 605 - 606
Author’s Reply to Jia et al.: “BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta‑Analysis” Francisco Jose Candido dos Reis Letter to the Editor 01 August 2022 Pages: 607 - 608
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma Suzette GirgisShun Xin Wang LinYusri Elsayed Correction Open access 01 August 2022 Pages: 609 - 609